SinoMab's novel IL-25 receptor-targeting antibody SM17 demonstrated exceptional efficacy in Phase 1b trials, with 91.7% of patients in the higher dose group achieving significant itch reduction compared to 0% in the placebo group.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.